SCHEMBL951322

SCHEMBL951322

FC(F)(F)c1cc(Cl)ccc1I

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C19 P33261 1/20 0.46
NOTUM Q6P988 1/20 0.42
KDM4E B2RXH2 1/20 0.41
TP53 P04637 1/20 0.39
MAPT P10636 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CYP3A4 P08684 1/20 0.37
TSHR P16473 1/20 0.37
MAPK1 P28482 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
TMPRSS4 Q9NRS4 2/20 0.36
HCAR1 Q9BXC0 1/20 0.36
POLQ O75417 1/20 0.36
PKM P14618 1/20 0.36
PDK2 Q15119 1/20 0.35
AR P10275 1/20 0.35
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30160661 1.00 RAB9A (0.46) RAB9ACYP1A2CYP2D6CYP2C19NOTUM
SCHEMBL4484774 0.82 RAB9A (0.42) RAB9ACYP1A2CYP2D6CYP2C19NOTUM
SCHEMBL16705617 0.80 AHR (0.44) RAB9ANOTUMKDM4ETP53SMN1; SMN2
SCHEMBL3789153 0.78 CYP3A4 (0.52) RAB9ACYP1A2CYP2D6CYP2C19KDM4E
SCHEMBL31303886 0.76 SLC6A4 (0.46) RAB9ACYP1A2CYP2D6CYP2C19KDM4E
SCHEMBL30867127 0.76 TSHR (0.54) RAB9ACYP1A2CYP2D6CYP2C19KDM4E
SCHEMBL987352 0.76 IDO1 (0.50) RAB9ACYP1A2CYP2D6CYP2C19NOTUM
SCHEMBL29649700 0.76 IDO1 (0.50) RAB9ACYP1A2CYP2D6CYP2C19NOTUM
SCHEMBL6058773 0.76 NOTUM (0.35) NOTUMTSHR
SCHEMBL657298 0.76 SLC6A4 (0.46) RAB9ACYP1A2CYP2D6CYP2C19KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240182477-A1 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE VIGIL NEUROSCIENCE, INC. 2024-06-06 US disclosed
US-11912711-B2 Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use AMGEN INC. (US) 2024-02-27 US disclosed
US-11884675-B2 Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use AMGEN INC. (US) 2024-01-30 US disclosed
CN-111170991-B Antiproliferative compounds and methods of synthesis thereof 细胞基因公司 2023-10-31 CN disclosed
EP-3594211-B1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF CELGENE CORP (US) 2023-10-25 EP disclosed
EP-3870295-B1 NOVEL TRICYCLIC COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE HOFFMANN LA ROCHE (CH) 2023-03-08 EP disclosed
US-20220387413-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF CELGENE CORP (US) 2022-12-08 US disclosed
WO-2022226667-A1 SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2022-11-03 WO disclosed
CN-114381026-A Sulfonated perfluoro-polyphenyl proton exchange membrane and preparation method thereof 董天都 2022-04-22 CN disclosed
US-11241423-B2 Antiproliferative compounds and methods of use thereof CELGENE CORPORATION (US) 2022-02-08 US disclosed
US-5747424-A HEATING AN AROMATIC DIKETONE WITH A SALT OF HYDROXYLAMINE IN A SOLVENT RHONE-POULENC AGRICULTURE LTD. (GB) 1998-05-05 US disclosed
US-5656573-A Herbicidal 4-substituted isoxazoles RHONE-POULENC AGRICULTURE LTD. (GB) 1997-08-12 US disclosed
US-5650533-A Intermediates to herbicidal 4-substituted isoxazoles RHONE-POULENC AGRICULTURE LTD. (GB) 1997-07-22 US disclosed
EP-0487357-B1 4 Benzoyl isoxazole derivatives RHONE POULENC AGRICULTURE (GB) 1997-07-02 EP disclosed
WO-1997018197-A1 NEW PROCESS FOR THE PREPARATION OF PHENYLIMIDAZOLIDINE DERIVATIVES HOECHST MARION ROUSSEL (FR) 1997-05-22 WO disclosed
US-5447954-A Antilipidemic agents SMITHKLINE BEECHAM P.L.C. (GB) 1995-09-05 US disclosed
EP-0639187-A1 PHENYLDERIVATE AS INHIBITORS OF ATP CITRATE LYASE SMITHKLINE BEECHAM PLC (GB) 1995-02-22 EP disclosed
WO-1993022304-A1 PHENYLDERIVATE AS INHIBITORS OF ATP CITRATE LYASE SMITHKLINE BEECHAM PLC (GB) 1993-11-11 WO disclosed
CN-1061596-A 4-Benzoylisoxazole Derivatives RHONE POULENC AGRICULTURE (GB) 1992-06-03 CN disclosed
EP-0487357-A1 4 Benzoyl isoxazole derivatives RHONE-POULENC AGRICULTURE LTD. (GB) 1992-05-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220387413-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF MCL1, MKI67, BAX RAB9A 3006/4885CYP1A2 2288/4885CYP2D6 1559/4885
US-11241423-B2 Antiproliferative compounds and methods of use thereof MCL1, MKI67, BAX RAB9A 3006/4885CYP1A2 2288/4885CYP2D6 1559/4885
US-20240182477-A1 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE MSR1, FPR2, CD14 RAB9A 2702/4885CYP1A2 417/4885CYP2D6 1342/4885
US-11912711-B2 Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use MSR1, FPR2, CD14 RAB9A 2702/4885CYP1A2 417/4885CYP2D6 1342/4885
US-11884675-B2 Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use MSR1, FPR2, CD14 RAB9A 2702/4885CYP1A2 417/4885CYP2D6 1342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.